Eli Lilly's shares rose 15% after announcing mid-stage trial results for its oral medication, orforglipron, showing an average weight loss of 16 pounds over 26 weeks in Type 2 diabetes patients. This performance outpaces Novo Nordisk’s Ozempic, which aids 6% weight loss. While orforglipron also lowered blood sugar by 1.3%, slightly less than Ozempic’s 2.1%, its needle-free delivery and superior weight management potential has garnered positive attention amid rising global obesity rates. Meanwhile, shares of Novo Nordisk dropped 3.9% due to competition concerns.
"The drug also lowered patients' blood sugar levels by 1.3% on average, while the overall efficacy of orforglipron in promoting weight loss and controlling diabetes has been met with enthusiasm."
"This represents a potentially major advance for patients seeking a needle-free option for weight and glucose management," Eli Lilly said in a statement.
Collection
[
|
...
]